Lionheart Health, Inc., through Leonhardt Ventures LLC, has filed a provisional patent application for a bioelectric stimulation platform designed to significantly enhance peptide uptake and biological effectiveness across oral, topical, and injectable delivery methods. The invention addresses a persistent challenge in both biotech and longevity medicine: translating promising peptide biology into consistent, real-world outcomes.
Current peptide delivery methods face significant efficiency losses. Up to 70% of intravenous delivery is lost, while up to 99.9% of oral and topical deliveries fail to reach target tissues. The new platform applies controlled bioelectric stimulation to enhance peptide efficacy and uptake, with early experimental data indicating improvements of up to 300 percent. This may enable lower dosing while maintaining or increasing therapeutic impact.
The technology is designed to improve absorption and signaling efficiency across key healthspan-related pathways, including klotho, sirtuins, sestrins, apelin, LIM, BDNF, SDF1, PDGF, VEGF, S100a, and related proteins. Lionheart Health is recognized for its leadership in klotho-based longevity research and was recently named a Top 40 semifinalist in the XPRIZE Healthspan competition. The company holds multiple issued patents related to klotho technologies, with additional applications pending.
The patent builds on decades of bioelectric medicine research conducted by Leonhardt Ventures and expands Lionheart Health's proprietary platform for modulating cellular environments to optimize peptide and protein activity. Precisely tuned bioelectric signals are designed to enhance barrier transport, receptor interaction, and downstream tissue-level effects.
"This filing represents a major step forward in making advanced peptide-based longevity interventions more efficient, predictable, and scalable," stated Howard J. Leonhardt, Executive Chairman, Inventor and co-CEO of Lionheart Health, Inc. and CEO of Leonhardt Ventures LLC. "By combining peptides with bioelectric signaling, we believe we can unlock significantly greater biological impact at lower doses, across multiple routes of administration."
The patent claims encompass oral, topical, and injectable peptide delivery enhanced by targeted bioelectric stimulation, with applications designed to support muscle, brain, immune, metabolic, aesthetic, cardiovascular, and regenerative health. Special emphasis is placed on peptides that enhance Klotho activity, a protein closely linked to aging regulation and cellular resilience.
Mechanisms described in the patent include enhanced transmembrane transport through modulated membrane potential, improved barrier permeability via temporary changes to tight junction behavior in the gut and skin, receptor sensitization to increase peptide binding efficiency, and intracellular trafficking optimization to reduce peptide degradation. The technology is designed to create synergistic Klotho signaling by favoring cellular environments that amplify Klotho-related pathways tied to longevity and tissue protection.
The newly filed intellectual property strengthens Lionheart Health's position at the intersection of bioelectric medicine and peptide therapeutics, creating opportunities for next-generation longevity and wellness protocols, licensed clinical and research applications, and integration into future Lionheart Health devices, programs, and clinical studies. The company plans to incorporate the technology into selected upcoming healthspan initiatives and investigational protocols, while pursuing strategic partnerships and licensing opportunities. More information about the company's initiatives can be found at http://www.lionhearthealthstim.com and http://www.LionheartLongevity.com.
